| S. No. |
Disease |
Phase |
Brief Description |
HCG
sites |
CTRI Number. |
Clinical
Trials.gov ID |
|
1 |
Metastatic Breast
Cancer |
I |
Trastuzumab, Paclitaxel and study drug (oral) in HER2 positive Metastatic breast cancer (first line) |
BIO |
CTRI/2009
091/000834 |
NCT00864175 |
|
2 |
HRPC |
III |
Docetaxel with or without study drug (oral) in
Metastatic hormone resistant Prostate cancer |
BIO |
CTRI/2009
091/000193 |
NCT00617669 |
|
3 |
NSCLC |
III |
Chemoradiation followed by consolidation
chemotherapy in locally advanced non squamous non
Small Cell lung Cancer |
BIO |
NCT006
86959 |
NCT00686959 |
|
4 |
HER2 negative
metastatic or locally recurrent breast cancer |
III |
Docetaxel with bevacizumab followed by maintenance
Bevacizumab with or without capecitabine in HER2 negative metastatic breast cancer |
BIO |
CTRI/2009
091/000423 |
NCT00929240 |
|
5 |
Pain Management |
III |
Fentanyl Sublingual Spray (Fentanyl SL Spray) for the treatment of Breakthrough cancer pain |
BIO |
NCT00
538863 |
NCT00538863 |
|
6 |
RCC |
IV |
Non Interventional Study of Advanced Renal Cell
Cancer receiving Sutent |
BIO |
CTRI/2009
091/000348 |
NCT00836745 |
|
7 |
Metastatic colorectal cancer |
III |
Chemotherapy with or without local treatment in colorectal cancer with liver metastasis |
BIO |
CTRI/2009
091/000295 |
NCT00440310 |
|
8 |
Colon and Colorectal
cancer under Fed conditions |
BE |
Capecitabine in colorectal or breast cancer patients- BE study |
BIO |
NA |
NA |
|
9 |
Glioblastoma |
III |
Chemoradiation with or without study drug in operated
Glioblastoma multiforme |
BIO |
CTRI/2009
091/000827 |
NCT00689221 |
